Can pCR Be an Early Clinical Trial Endpoint? Initiative Aims to Answer That Question

Regulating Artificial Intelligence

Experts Debate Addition of Frontline Chemotherapy for EGFR+ NSCLC

Should Biomarkers Be Used in the Clinical Management of ES-SCLC?

FLAURA 2 Post-progression Outcomes Demonstrate Consistent Benefit, Favor Combination Arm

Antibody Drug Conjugates: Diamonds in the Rough?

The Promise of Artificial Intelligence-Aided Pathology in Thoracic Oncology

Challenges of Systemic Therapy for Patients with EGFR-mutated Lung Cancer After Progression on Targeted Therapy

No PFS, OS Benefit Seen in Final Results from PACIFIC-2

MARIPOSA-2 Post-progression Analysis Favors Amivantamab-Chemotherapy Combination

Can Artificial Intelligence Identify Those at High Risk and Shift the Lung Cancer Screening Paradigm?

Mounting Evidence Supporting Neoadjuvant ChemoIO Means Surgeons Must Adapt